Shots:
The US FDA has granted FTD to abelacimab (factor XI inhibitor) for the treatment of thrombosis associated with cancer
The P-III CAT program comprises (ASTER) study to evaluate the effect of abelacimab vs apixaban & (MAGNOLIA) study of abelacimab vs dalteparin on VTE recurrence and bleeding in ~2700 patients with cancer-associated VTE across 220 sites in 20+ countries
In a PK/PD study, abelacimab (IV) delivered profound Factor XI suppression within 1hr. after the start of therapy and maintained near maximal inhibition for ~30 days. In the P-II study, the therapy showed an 80% reduction in the rate of venous thromboembolism over enoxaparin as measured 10 days after surgery
Ref: PRNewswire | Image: Anthos Therapeutics
